Nutex Health Q1 revenue rises 2.2% but misses estimates

Overview

• US healthcare operator's Q1 revenue rose 2.2% but missed analyst expectations

• Net income attributable to Nutex Health more than doubled year-over-year

• Revenue growth driven by higher acuity claims and favorable dispute resolution outcomes

Outlook

• Company plans to open three new hospitals later in 2026

• Nutex Health targets sustainable pace of three to five hospital openings annually

• Company to begin selective self-development of new facilities through real estate division in 2026

Result Drivers

• IDR OUTCOMES - Co said favorable outcomes in the Independent Dispute Resolution process supported hospital revenue

• STOCK-BASED COMPENSATION DECLINE - Net stock-based compensation expense fell sharply year-over-year

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Nutex Health Inc is $215.00, about 91.9% above its April 29 closing price of $112.02

• The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.